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Aim: To assess the safety and efficacy of an intravenous immunoglobulin (IVIG) 10% preparation
(Panzyga R©; Octapharma AG, Lachen, Switzerland) in predominantly antibody-deficient children with pri-
mary immunodeficiency disease. Methods: Data from two prospective, open-label and noncontrolled mul-
ticenter Phase III studies of IVIG 10% that included 25 patients <16 years of age were analyzed for effi-
cacy, pharmacokinetics and safety. Results: The rate of serious bacterial infections was 0.04/patient-year.
A maximal infusion rate of 0.14 ml/kg/min was achieved in 82% of pediatric patients (n = 9). Infusions of
immunoglobulin G trough levels between infusions remained ≥5–6 g/l; median half-life was 32.79−36.62
days. Abdominal pain, headache and chills were the most common treatment-related adverse events. Con-
clusion: IVIG 10% is safe and effective for the treatment of predominantly antibody-deficient children.
High infusion rate of up to
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Primary immunodeficiency diseases (PID) encompass over 320 molecularly defined disorders that affect the
development and/or function of the adaptive and innate immune systems [1]. Children with antibody deficiency
present with recurrent, often severe, bacterial infections, which affect the respiratory system, GI tract, skin and
other organs [2,3]. Infusions of immunoglobulin G (IgG) provide these patients with specific antibodies to prevent
severe bacterial and viral infections and decrease hospitalization [4–7].
Two open-label Phase III studies were conducted to investigate efficacy, safety and pharmacokinetics of a novel
intravenous immunoglobulin (IVIG) 10% preparation (Panzyga R©; Octapharma AG, Lachen, Switzerland) in adult
and pediatric patients with antibody deficiency [8]. Based on these studies, IVIG 10% was proven to be effective
and safe in both pediatric and adult patients. The present report separately analyzed data on the use of IVIG 10%
administered to antibody-deficient children aged 2–15.9 years, over a 12- to 15-month study period.
Methods
Study medication
IVIG 10% (Panzyga) is a high-purity, glycine-stabilized, human normal immunoglobulin solution with a physiologic
osmolality of 240–310 mOsmol/kg for intravenous administration, supplied in a liquid formulation.
Study design
Data for this analysis came from two prospective, open-label, noncontrolled, nonrandomized, multicenter, and
Phase III studies [8]. The 12-month main study, conducted in the USA and Europe, enrolled 51 patients aged 2–75
years (NGAM-01; ClinicalTrials. gov record: NCT01012323). The 3-month extension study enrolled 21 patients
aged 6–75 years, who completed the main study at USA study centers (NGAM-05; ClinicalTrials. gov record:
NCT01313507) and followed the same infusion schedule.
The primary objective of the pediatric study was to investigate the efficacy of IVIG 10% in preventing serious
bacterial infections (SBIs) in children aged 2–15.9 years, with secondary objectives being the evaluation of phar-
macokinetics, safety and tolerability. The purpose of the extension study was to evaluate and collect additional
safety and tolerability data, particularly when rapid infusion rates were employed. Pediatric patients with common
variable immunodeficiency (CVID; n = 20) or X-linked agammaglobulinemia (XLA; n = 5) were included in this
analysis.
Patients qualifying for the study received 17 or 13 infusions over a 12-month period, depending on whether
their treatment interval was 3 or 4 weeks, respectively. Dosages of 200–800 mg/kg body weight every 21 (± 3)
or 28 (± 3) days remained constant throughout the study and were based on the dose and interval of the IVIG
product the patient had been receiving prior to enrollment. During the extension study, patients received a total of
five or four infusions, depending on the treatment interval of 3 or 4 weeks, respectively.
If the initial infusion rate of 0.01 ml/kg/min (60 mg/kg/h) for 30 min was tolerated, the rates were increased
to maximum infusion rates of 0.08 ml/kg/min (480 mg/kg/h) during the main study and 0.14 ml/kg/min
(840 mg/kg/h) during the extension study.
Prior approval of the protocols was obtained from each study site’s Institutional Review Board. For minors, both
written informed assent (as applicable for the study site) and consent from the patient and the patient’s parent/legal
guardian, were required.
Treatment outcomes
Main study
The primary end point (efficacy) was the rate of annualized SBIs per patient-year on treatment, defined as
bacteremia/sepsis, bacterial meningitis, osteomyelitis/septic arthritis, bacterial pneumonia and visceral abscess.
Secondary efficacy end points, collected by the investigators from patient diaries at each visit, included: number of
episodes per patient-year of annualized other infections; type, severity and time to resolution of these infections;
antibiotic usage including days on antibiotics; number of days of school or work missed; hospitalizations due to
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infection; number of days and reasons for hospitalization and number of febrile episodes (all per patient-year on
treatment).
Pharmacokinetic end points included maximum plasma concentration (Cmax), time from start of infusion to
Cmax (Tmax), trough plasma concentration (Cmin), half-life (t 1
2
), area under the concentration-time curve (AUC)
until end of the dosing interval (AUCτ) and elimination rate constant (kel). Measured variables included total
serum IgG and IgG subclasses. Blood samples were taken at 15 min, 1, 24 and 72 h and 7, 14 and 21 days (3-week
schedule) or 28 days (4-week schedule) after completion of the ninth or seventh infusions, respectively.
Safety parameters included: occurrence of adverse events (AEs), temporally (during or within 72 h postinfusion)
associated AEs, proportion of infusions with ≥1 temporally associated AE; AEs related to infusion rate; vital signs;
hematology parameters (complete blood count with white blood cell differential, haptoglobin); clinical chemistry;
direct Coombs test; urinalysis and physical examination. Treatment-emergent AEs were defined as AE with onset
or worsening after start of the first infusion. AEs were categorized as mild, moderate or severe and the relationship
to IVIG (probable, possible, unlikely, or unrelated) was determined by the investigator.
Extension study
Safety parameters included physical examination, vital sign monitoring, type and frequency of AEs, and laboratory
values described above.
Statistical analysis
The statistical software package used for efficacy and safety analyses was SAS, version 9.1 or higher (SAS Institute,
NC, USA). Pharmacokinetics analyses were performed using Phoenix WinNonlin, version 6.2 (Certara, NJ, USA)
or later.
Details as to target number of patients and sufficient statistical power are reported elsewhere [8].
The rate of annualized SBIs for each patient was represented as point estimates with 99% CI, calculated as:
r = (Total number of SBIs) / (Patient-years on study drug).
Analysis sets
Efficacy end points were analyzed in all enrolled patients who had at least one post-treatment diary entry containing
infection data. Safety end points were analyzed in all patients who received at least a part of one treatment.
Pharmacokinetic end points were analyzed in all patients with concentration data for ≥1 of the preinfusion trough
levels. All patients who received ≥1 dose of study drug were included in the analysis of end points in the extension
study.
Results
Patient demographics & disposition
Main study
Eight study centers enrolled 25 pediatric patients (three children aged 2–5.9 years; 10 children aged 6–11.9
years; 12 adolescents aged 12–15.9 years) into two treatment groups (infusions every 3 or 4 weeks), governed by
the prestudy infusion interval. All patients received at least nine infusions and had at least one post-treatment
diary entry containing infection data. One adolescent patient exited the study after nine 4-weekly infusions
because a substantially increased IVIG dose was required (investigator’s judgment) due to worsening of pre-existing
bronchiectasis. One child had a major protocol violation (missing two infusion visits). Both were included in the
analysis.
Patient demographic and baseline characteristics, stratified according to age, are presented in Table 1. The
majority (≥70%) of patients in each age group were male. All patients were Caucasian. 20 patients were diagnosed
with CVID and five with molecularly confirmed XLA.
Extension study
All 11 patients who were enrolled at USA study centers (9 CVID, 2 XLA) aged 6–15.9 years completed the study
during which the maximum infusion rate was increased to 0.14 ml/kg/min (840 mg/kg/h) in nine patients and to
0.12 ml/kg/min (720 mg/kg/h) in the remaining two patients. The demographics were similar to those included
in the main study (Table 1).
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Table 1. Baseline characteristics and demographics of pediatric patients included in studies NGAM-01 and NGAM-05.
Characteristic/demographic Children 2–5.9 years Children 6–11.9 years Adolescents 12–15.9 years
NGAM-01 (n = 3) NGAM-05 (n = 0) NGAM-01 (n = 10) NGAM-05 (n = 8) NGAM-01 (n = 12) NGAM-05 (n = 3)
Age, years
Mean ± SD (range) 4.0 ± 1.7 (2–5) – 7.2 ± 0.9 (6–9) 8.0 ± 1.2 (6–10) 13.7 ± 1.0 (12–15) 14.0 ± 1.0 (13–15)
Gender, n (%)
Male 3 (100) – 7 (70.0) 6 (75.0) 10 (83.3) 1 (33.3)
Female 0 – 3 (30.0) 2 (25.0) 2 (16.7) 2 (66.7)
Diagnosis, n (%)
CVID 2 (66.7) – 8 (80.0) 6 (75.0) 10 (83.3) 3 (100.0)
XLA 1 (33.3) – 2 (20.0) 2 (25.0) 2 (16.7) 0 (0.0)
Treatment schedule, n (%)
3-week 1 (33.3) – 4 (40.0) 4 (50.0) 8 (66.7) 3 (100.0)
4-week 2 (66.7) – 6 (60.0) 4 (50.0) 4 (33.3) 0
Bodyweight, kg
Mean ± SD (range) 19.9 ± 8.0 (13–29) – 25.6 ± 5.9 (19–36) 26.3 ± 5.3 (20–36) 57.3 ± 10.8 (40–76) 53.6 ± 10.9 (44–66)
BMI, kg/m2
Mean ± SD (range) 16.7 ± 1.8 (15–19) – 16.3 ± 1.6 (15–19) NA 21.9 ± 4.4 (16–31) NA
CVID: Common variable immunodeficiency; kg: Kilogram; m: Meter; NA: Not available; SD: Standard deviation; XLA: X-linked agammaglobulinemia.
Table 2. Rate of serious bacterial infections and other infections in pediatric patients included in study NGAM-01.
Children Adolescents
2–5.9 years (n = 3) 6–11.9 years (n = 10) 12–15.9 years (n = 12)
SBI, n (%) 0 1 (10.0) 0
Annualized SBIs per patient-year (99% CI) – 0.1 (0.0098–1.0240) –
Other infections, n (%) 3 (100.0) 9 (90.0) 10 (83.3)
Number of other infections 20 38 43
Intensity
Severe 0 0 1
Moderate 2 8 22
Mild 18 30 20
Annualized OIs per patient-year (95% CI) 6.7 (2.3–19.4) 3.8 (2.1–7.0) 3.7 (1.8–8.0)
Time to resolution of other infections, days
Median (range) 5 (0–73) 9 (0–70) 10 (1–132)
Type of other infection, number of patients/number of infections
Ear infections 2/4 3/4 2/3
Eye infections 0 1/1 0
GI tract infections 2/9 3/3 3/5
Respiratory tract infections
Upper 2/5 6/18 8/27
Lower 2/2 4/4 3/3
Skin infections 0 3/4 0
Other 0 2/4 3/5
OI: Other infection; SBI: Serious bacterial infection; SD: Standard deviation.
Efficacy
Primary end point
The overall rate of annualized SBIs per patient-year was 0.04. The sole reported SBI was an episode of bacterial
pneumonia (Table 2) in an 8-year-old boy with CVID on a 4-week schedule who had missed two nonconsecutive
infusions that resulted in low IgG trough levels, possibly explaining the occurrence of the SBI.
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Secondary end points
Data on nonserious infections are presented in Table 2. The proportion of patients experiencing annualized other
infections ranged from 83 to 100% in the three pediatric subgroups, with corresponding per patient-year rates of
3.7–6.7. The majority were mild, including ear and eye infections, GI, respiratory tract, or skin infections; the time
to resolution was 5–10 days.
During the main study, all but two patients (23/25; 92%) used antibiotics, given therapeutically more often
than prophylactically (82 vs 18%). The number of episodes when antibiotics were used ranged from 3.01 to 4.34
per patient-year, with the total number of treatment days per patient-year being 24.5 in children aged 2–5.9 years,
121.3 in children aged 6–11.9 years and 151.8 days in adolescents aged 12–15.9 years (data not shown). Adolescent
patients had the highest rate of treatment days per patient-year of prophylactic antibiotics compared with the two
younger age groups (124.2 vs 73.7 [children aged 6–11.9 years] and 0 days [children aged 2–5.9 years]).
The proportion of patients missing school due to infections was 100% (3 of 3), 70% (7 of 10) and 75% (9 of
12) in the 2- to 5.9-year, 6- to 11.9-year and 12- to 15.9-year age groups, respectively. The corresponding total
numbers of episodes (number of days per person-year) of absence from school in these groups were 11 (7.4 days), 16
(3.2 days) and 28 (6.7 days). The rate of absences per patient-year was highest among patients in the youngest age
group, both with respect to the rate of absences and of total number of days absent (Figure 1). Fever, as determined
by the investigator, was reported in six patients (24%). Adolescents had the lowest rate of febrile episodes per
patient-year (0.174), followed by children aged 2–5.9 years (0.336) and those aged 6–11.9 years (0.502). There
were no hospitalizations due to infection in this population.
Pharmacokinetics
As expected, the pharmacokinetic profile of IVIG 10% was characterized by a steep decline from peak concentrations
observed at the end of the infusion, followed by a slow terminal elimination phase (data not shown). The median
total IgG Cmax ranged from 16.1 to 19.3 g/l and was typically reached at the end of infusion. Median Tmax in
hours (minimum, maximum), which was measured from the beginning of the infusion, was 2.50 (2.42, 3.22) in
children aged 2–5.9 years, 2.83 (2.25, 3.33) in children aged 6–11.9 years and 2.68 (2.08, 24.75) in adolescents
aged 12–15.9 years. Median AUCτ was 6474.3, 7612.8 and 6825.9 h·g/l, respectively and median t 1
2
in days
(minimum, maximum) was 36.09 (27.70, 44.42), 36.62 (28.55, 65.91) and 32.79 (19.77, 76.63), respectively
(data not shown).
Serum IgG trough levels remained constant over the duration of the study for both treatment schedules and
across all age groups and were above the recommended trough levels of ≥5–6 g/l [9]: after the first infusion, the
median trough levels of all pediatric age groups were 8.0–9.7 g/l, while follow-up levels at the end of the study
were 8.2–9.9 g/l.
Safety
Main study
The average dose of IgG per bodyweight was 0.535, 0.497 and 0.484 g/kg for patients 2–5.9 years, 6–11.9 years
and 12–15.9 years, respectively, and was similar between patients on the 3-week and 4-week schedules, implying
that patients on the 3-week schedule received a higher weekly dose (means ranging from 0.162 to 0.179, with a
total mean of 0.169 for 3-week schedule infusions versus means ranging from 0.115 to 0.135, with a total mean of
0.120 for 4-week schedule infusions; being significantly different only in the 6–11.9 years group, p = 0.01).
There were no deaths and no patient withdrew from the trial due to AEs (Table 3). 24 of 25 patients evaluated
for safety experienced at least one AE. One adolescent patient reported two episodes of serious AEs caused by
exacerbation of symptoms associated with bronchiectasis and one episode of moderate bronchospasm, but none of
these serious AEs were considered to be related to study medication [8]. Five patients (1 on 3-week infusion schedule
and 4 on 4-week schedule) had at least one AE that the investigator considered to be related to study medication,
the most frequent being abdominal pain, headache and chills. Infusion-related AEs (i.e., occurring during or within
72 h of receiving an infusion) were reported by 21 patients (84%) and consisted of pyrexia, headache, sinusitis,
abdominal pain, chills, fatigue and infusion-site discomfort (Table 3). There were no notable changes during the
study in laboratory parameters, vital signs and physical examination.
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Figure 1. School absences due to infections. Shown as (A) rate per person-year and (B) number of days absent per
person-year.
Extension study
The average dose of IgG given at each infusion during the extension study was 0.528 and 0.533 g/kg bodyweight
for patients aged 6–11.9 years (n = 8) and 12–15.9 years (n = 3), respectively (means ranging from 0.178 to 0.183,
with a total mean of 0.181 for 3-week schedule infusions versus mean of 0.125 for 4-week schedule infusions;
being significantly different in the 6-11.9 years group; p = 0.046).
No deaths or withdrawals occurred due to AEs (Table 3) and no serious AEs were reported during the extension
phase; AEs, all mild to moderate, were experienced by 10 patients (91%). Two patients aged 6–11.9 years (18%)
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Table 3. Summary of adverse events that occurred in pediatric patients included in studies NGAM-01 and NGAM-05.
Adverse events Children 2–5.9 years Children 6–11.9 years Adolescents 12–15.9 years Total
NGAM-01 (n = 3) NGAM-01
(n = 10)
NGAM-05 (n = 8) NGAM-01
(n = 12)
NGAM-05 (n = 3) NGAM-01
(n = 25)
NGAM-05
(n = 11)
AEs, number 41 106 33 107 6 254 39
SAEs, number 0 0 0 3a 0 3 0
AEs, n (%)
Any AE 3 (100.0) 9 (90.0) 7 (87.5) 12 (100.0) 3 (100.0) 24 (96.0) 10 (90.9)
Related AE‡ 2 (66.7) 0 2 (25.0) 3 (25.0) 0 5 (20.0) 2 (18.2)
Serious AE 0 0 0 1 (8.3) 0 1 (4.0) 0
Severe AE 0 0 0 2 (16.7) 0 2 (8.0) 0
Related AEs, n (%)†
Abdominal pain 2 (66.7) 0 1 (12.5) 0 0 2 (8.0) 1 (9.1)
Headache 1 (33.3) 0 1 (12.5) 1 (8.3) 0 2 (8.0) 1 (9.1)
Chills 1 (33.3) 0 0 1 (8.3) 0 2 (8.0) 0
Infusional AEs, n (%)§ 3 (100.0) 7 (70.0) 4 (50.0) 11 (91.7) 1 (33.3) 21 (84.0) 5 (45.5)
Pyrexia 1 (33.3) 3 (30.0) 0 1 (8.3) 0 5 (20.0) 0
Headache 1 (33.3) 1 (10.0) 1 (12.5) 1 (8.3) 0 3 (12.0) 1 (9.1)
Sinusitis 0 1 (10.0) 0 2 (16.7) 1 (33.3) 3 (12.0) 1 (9.1)
Abdominal pain 2 (66.7) 0 1 (12.5) 0 0 2 (8.0) 1 (9.1)
Chills 1 (33.3) 0 0 1 (8.3) 0 2 (8.0) 0
Fatigue 0 0 0 2 (16.7) 0 2 (8.0) 0
Infusion-site pain 0 0 0 2 (16.7) 0 2 (8.0) 0
Note: NGAM-05 study did not enroll children 6 years of age.
†Bronchiectasis/bronchospasm-related symptoms observed in one patient.
‡Any event possibly or probably related, in a total of two or more patients.
§Any event occurring during IVIG 10% infusion or up to 72 h after the end of the infusion, in a total of two or more patients.
AE: Adverse event; SAE: Serious adverse event.
had AEs considered to be treatment-related (during the highest infusion rate, one each on 3-week and 4-week
infusion schedule) and included abdominal pain, headache and an erythematous and edematous hand due to a
tight infusion tourniquet. Five patients (46%) experienced an infusion-related AE, none of which was reported
by more than one patient (Table 3). Flow rate was decreased and infusion temporarily interrupted for one patient
with headache, but permanent discontinuation was not necessary. There were no notable safety concerns based on
physical examination or changes in laboratory parameters.
Discussion
This subanalysis of pediatric patients with predominantly antibody-deficient PID demonstrated that the study drug
IVIG 10% (Panzyga) is effective, well tolerated and safe for both children and adolescents during 12–15 months
of treatment. Median serum IgG trough levels were above the recommended therapeutic level [9] when IVIG 10%
was administered on a 3- or 4-week schedule. Pharmacokinetics were similar to those reported in adults [8,10–12].
Most of the data presented here was published combined with data from adult patients previously [8].
There is a paucity of studies investigating IVIG 10% preparations in children. However, in a multicenter, open-
label, Phase III clinical trial of IVIG 10% (Privigen R©, CSL Behring AG, Bern, Switzerland), patients with PID,
39% of whom were under 16 years of age, had similar results to the current study, with 97% of patients reporting
at least one AE during the study, which were mostly mild or moderate in intensity [13].
The primary purpose of prophylactic IgG infusions is to prevent serious, detrimental infections rather than to
prevent minor infections which can occur as frequently as 16-times per year in children without PID attending
daycare [14]. Therefore, the annualized SBI rate of 0.04 per patient-year and annualized other infection rate of
3.7−6.7 per patient-year are well in line with those observed in normal, otherwise healthy children. The annual
rate of days missed from school recorded in this study was comparable to other studies of immunocompromised
and nonimmunocompromised individuals [13,15]. While antibiotic use may appear high (92% of all patients), it
should be noted that this is in line with published data [13], and concurrent prophylactic antibiotic therapy is
recommended by most immunologists for patients with PID and chronic infections [16].
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Minor infusion reactions were common, but not different from those seen with current commercially available
products [11,13] and did not result in withdrawal from the study. An infusion rate as high as 0.14 ml/kg/min
(840 mg/kg/h) was achieved in nine of 11 patients (aged 6–15.9 years), with the remaining two achieving an
infusion rate of 0.12 ml/kg/min, without a corresponding increase in the rate of drug-related AEs, by incrementally
increasing the dose every 15 min from the starting rate of 0.01 ml/kg/min, thus shortening the duration of the
infusion substantially compared with the standard maximum rate of 0.08 ml/kg/min [17].
Despite the small patient population, this sub-analysis provides valuable information on the efficacy and safety
of IVIG 10% for the treatment of children with antibody-deficient PID.
In summary: IVIG 10% (Panzyga) is safe and effective for the treatment of children with antibody-deficient
PID; it prevents serious infections, and has pharmacokinetics similar to those observed in adults and trough levels
that exceed levels considered protective. Panzyga is well tolerated when administered at the highest infusion rate
studied to date in pediatric patients.
Summary points
• Intravenous immunoglobulin 10% (Panzyga R©; Octapharma AG, Lachen, Switzerland) is a high-purity,
glycine-stabilized, human normal immunoglobulin preparation with physiologic osmolality.
• Intravenous immunoglobulin 10% was found to be safe and effective in the treatment of antibody-deficient
children <16 years of age.
• The rate of annualized serious bacterial infections per patient-year was 0.04.
• Serum infusions of immunoglobulin G trough levels were above the recommended levels of ≥5–6 g/l between
infusions and remained constant throughout the study period.
• Infusion-related adverse events included pyrexia, headache, sinusitis, abdominal pain, chills, fatigue and
infusion-site discomfort and were mainly of mild-to-moderate intensity.
• No deaths or withdrawals due to adverse events were reported during the 15-month study period.
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